Clinical Trial Update: Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

View source ↗

Summary

Post-trial access update for guselkumab in participants with familial adenomatous polyposis; the trial is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Adenomatous Polyposis Coli | Status: NO_LONGER_AVAILABLE